Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21390155 | 1.00 | ATF4 (0.56) | ATF4HDAC8 | |
| SCHEMBL21390157 | 1.00 | ATF4 (0.56) | ATF4HDAC8 | |
| SCHEMBL23294677 | 1.00 | ATF4 (0.56) | ATF4HDAC8 | |
| SCHEMBL21384496 | 1.00 | ATF4 (0.56) | ATF4HDAC8 | |
| SCHEMBL21389995 | 0.92 | ATF4 (0.59) | ATF4HDAC8 | |
| SCHEMBL29901237 | 0.87 | ATF4 (0.53) | ATF4HDAC8 | |
| SCHEMBL23706884 | 0.87 | ATF4 (0.53) | ATF4HDAC8 | |
| SCHEMBL21384356 | 0.87 | ATF4 (0.68) | ATF4 | |
| SCHEMBL23294709 | 0.86 | ATF4 (0.56) | ATF4 | |
| SCHEMBL23294711 | 0.86 | ATF4 (0.56) | ATF4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240140919-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2024-05-02 | — | — | US | disclosed |
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2023-08-10 | — | — | US | disclosed |
| US-20210130308-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. | 2021-05-06 | — | — | US | disclosed |
| EP-3768660-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | Denali Therapeutics Inc. (US) | 2021-01-27 | — | — | EP | disclosed |
| WO-2019183589-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | DENALI THERAPEUTICS INC. (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250072-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | ATF4 118/4885HDAC8 2068/4885 |
| US-20210130308-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | ATF4 118/4885HDAC8 2068/4885 |
| US-20240140919-A1 | MODULATORS OF EUKARYOTIC INITIATION FACTOR 2 | EIF2A, EIF4A2, EIF4EBP1 | ATF4 118/4885HDAC8 2068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.